Dr. Lal PathLabs Limited

NSEI:LALPATHLAB Stock Report

Market Cap: ₹245.5b

Dr. Lal PathLabs Management

Management criteria checks 2/4

Dr. Lal PathLabs' CEO is Shankha Banerjee, appointed in May 2024, has a tenure of less than a year. directly owns 0.028% of the company’s shares, worth ₹69.27M. The average tenure of the management team and the board of directors is 4.7 years and 5.7 years respectively.

Key information

Shankha Banerjee

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.03%
Management average tenure4.7yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Oct 26
Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results

Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Oct 24
Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong

Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

Oct 06
Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Jul 28
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

May 21
We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve

What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

May 01
What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Apr 13
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Mar 06
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely

Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Feb 04
Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next

Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Dec 28
Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Nov 17
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Oct 12
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around

Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Jul 07
Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 10
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Feb 13
Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital

Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dec 29
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

Sep 21
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends

These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Sep 01
These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well

Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Jul 31
Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00

Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Jun 23
Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital

Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

Jun 11
Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?

CEO

Shankha Banerjee

less than a year

Tenure

Mr. Shankha Banerjee serves as Chief Executive Officer of Group & Associates Companies at Dr. Lal PathLabs Limited. He served as Chief Operating Officer at Dr. Lal PathLabs Limited since 2020. He had been...


Leadership Team

NamePositionTenureCompensationOwnership
Arvind Lal
Executive Chairman29.8yrs₹30.14m32.93%
₹ 80.8b
Om Manchanda
MD & Director4.7yrs₹46.45m1.01%
₹ 2.5b
Vandana Lal
Executive Directorno data₹24.18m19.3%
₹ 47.4b
Shankha Banerjee
Chief Executive Officerless than a yearno data0.028%
₹ 69.3m
Ved Goel
Group CFO & CEO of International Business6.3yrs₹7.30m0.014%
₹ 35.5m
Jai Meena
Chief Operating Officer2.7yrsno datano data
Munender Soperna
Chief Information & Digital Officer10.5yrsno data0.025%
₹ 61.6m
Vinay Gujral
Company Secretary & Compliance Officer1.7yrsno data0%
₹ 0
Manoj Garg
Group Chief Human Resources Officer10.2yrsno data0.033%
₹ 80.1m

4.7yrs

Average Tenure

63.5yo

Average Age

Experienced Management: LALPATHLAB's management team is considered experienced (4.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Arvind Lal
Executive Chairman29.8yrs₹30.14m32.93%
₹ 80.8b
Om Manchanda
MD & Director13.8yrs₹46.45m1.01%
₹ 2.5b
Vandana Lal
Executive Director29.8yrs₹24.18m19.3%
₹ 47.4b
Arun Duggal
Lead Independent Director1.8yrs₹3.85mno data
Rajit Mehta
Independent Director1.4yrs₹1.56mno data
Rahul Sharma
Non Executive Director19.4yrs₹2.65m0.025%
₹ 61.9m
Rohit Bhasin
Independent Non-Executive Director2.1yrs₹2.60mno data
Somya Satsangi
Independent Director5.8yrs₹2.70mno data
Archana Erdmann
Non-Executive Director5.6yrs₹2.25m1.85%
₹ 4.5b
Gurinder Singh Kalra
Independent Director1.4yrs₹1.56mno data

5.7yrs

Average Tenure

63yo

Average Age

Experienced Board: LALPATHLAB's board of directors are considered experienced (5.7 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 23:21
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dr. Lal PathLabs Limited is covered by 44 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
null nullAntique Stockbroking Ltd.
Harith AhamedAvendus Spark